

The Health Service (Benefit) (Limited List) (Pharmaceutical Benefit) (Amendment No. 2) Regulations, 2021

<i>Made</i>	13 th April, 2021
<i>Coming into operation</i>	14 th April, 2021
<i>Laid before the States</i>	, 2021

THE COMMITTEE FOR HEALTH & SOCIAL CARE, in exercise of the powers conferred on it by sections 10 and 35 of the Health Service (Benefit) (Guernsey) Law, 1990^a and section 1 of the Health Service (Benefit) (Limited Lists) Ordinance, 2004^b, and all other powers enabling it in that behalf, hereby makes the following Regulations:-

Amendment to the 2004 Regulations.

1. In the Schedule to the Health Service (Benefit) (Limited List) (Pharmaceutical Benefit) Regulations, 2004^c ("the 2004 Regulations") -

^a Ordres en Conseil Vol. XXXII, p. 192; amended by Order in Council No. IX of 2003; No. II of 2011; No. IV of 2018; Recueil d'Ordonnances Tome XXVI, pp. 177 and 483; Ordinance Nos. XXII and XXVII of 2002; Nos. XXI and XXXIII of 2003; No. XLII of 2006; No. XLIII of 2007; No. XXII of 2015; Nos. IX and XLIV of 2016; and No. XVI of 2020. Applied with modifications by Recueil d'Ordonnances Tome XXV, p. 204; Tome XXVI, p. 484; Tome XXVII, p. 200; and Tome XXVIII, p. 1.

^b Ordinance No. XIII of 2004; amended by No. XXXIV of 2013 and No. XXV of 2017.

^c G.S.I. No. 9 of 2004 as amended by G.S.I. No. 42 of 2004; No's 18, 25 and 38 of 2005; No's 12, 18, 26, 36 and 46 of 2006; No's 3, 5, 6, 16, 17 and 32 of 2007; No's 11, 23, 29, 31, 47, 50 and 76 of 2008; No's 16, 35, 43, 47 and 56 of 2009; No's 5, 32, 48, 88, 91 and 99 of 2010; No's 5, 13, 19, 37, 38 and 52 of 2011; No's 5, 25, 33 and 52 of 2012; No's 5, 27, 35, 42, 68, 78 and 87 of 2013; No's 8, 11, 16, 25, 57, 69 and 99 of 2014; No's 9, 33 and 106 of 2015; No's 10, 17, 25, 31 and


- (a) insert the entries set out in Schedule 1 to these Regulations in the appropriate places and under the appropriate headings, and
- (b) for each pharmaceutical benefit in column 3 of Schedule 2 to these Regulations listed in the Schedule to the 2004 Regulations (under the reference and heading in columns 1 and 2 of Schedule 2 to these Regulations respectively), substitute the corresponding pharmaceutical benefit in column 4 of Schedule 2 to these Regulations.

Citation, commencement and extent.

2. (1) These Regulations may be cited as the Health Service (Benefit) (Limited List) (Pharmaceutical Benefit) (Amendment No. 2) Regulations, 2021, and shall come into force on the 14th day of April, 2021.

(2) These Regulations shall have effect in the Islands of Guernsey, Alderney, Herm and Jethou.

Dated this 13th day of April, 2021.



A. H. BROUARD

President of the States Committee for Health & Social Care

For and on behalf of the Committee

SCHEDULE 1

Reg. 1(a)

ENTRIES TO BE INSERTED IN THE SCHEDULE TO THE 2004 REGULATIONS

British National Formulary (BNF) Section	Heading	Pharmaceutical Benefit
8.3.4.2	Hormone Antagonists (Anti-androgens)	Enzalutamide, film coated tablets 40mg, 80mg (PEH Pharmacy dispensing, on-island Consultant Oncologist prescribing and in accordance with NICE TA number 316 or any revision thereof only)
4.10.1	Alcohol dependence	Nalmefene, film-coated tablets, 18mg (CDAT consultant Initiation and In accordance with NICE TA number 325 or any revision thereof only)
8.3.4.2	Hormone Antagonists (Anti-androgens)	Enzalutamide, film coated tablets 40mg, 80mg (PEH Pharmacy dispensing, on-island Consultant Oncologist prescribing and in accordance with NICE TA number 377 or any revision thereof only)
13.5.3	Drugs affecting the immune response	Ixekizumab, solution for injection in pre-filled syringes and prefilled pens, 80mg. (In accordance with NICE TA number 537 or any revision thereof only)
13.5.3	Drugs affecting the immune response	Tildrakizumab, solution for injection in pre-filled syringe, 100mg (In accordance with NICE TA number 575 or any revision thereof only)
13.5.3	Drugs affecting the immune response	Risankizumab, solution for injection in pre-filled syringe, 75 mg (In accordance with NICE TA number 596 or any revision thereof only)
9.1.4	Drugs used in platelet disorders	Lusutrombopag, Film-coated tablets, 3mg (In accordance with NICE TA number 617 or any revision thereof only)
9.1.4	Drugs used in platelet disorders	Avatrombopag, Film-coated tablets, 20mg (In accordance with NICE TA number 626 or any revision thereof only)

British National Formulary (BNF) Section	Heading	Pharmaceutical Benefit
4.7.4.2	Prophylaxis of migraine	Fremanezumab, solution for injection pre-filled syringes, pre-filled pens 150mg per ml (In accordance with NICE TA number 631 or any revision thereof only)
10.1.3	Drugs that suppress the rheumatic disease	Upadacitinib (as Upadacitinib hemihydrate) prolonged-release tablets 15 mg. (In accordance with NICE TA number 665 or any revision thereof only)
3.4.2	Allergen immunotherapy	Mepolizumab, powder for solution for injection, solution for injection in pre-filled pen and prefilled syringe, 100mg. Must be prescribed by brand name. (In accordance with NICE TA number 671 or any revision thereof only)
8.2	Drugs affecting the immune response	Glatiramer_Inj 40mg VI + Dil
Appliances	Insulin pump accessories	Freestyle Libre 2 Sensor: Maximum of two sensors per 28 days. For patients below 18 years, with type 1 diabetes and on the advice of a local Consultant Paediatrician only. For patients 18years and over, with type 1 Diabetes, subject to protocol and on the advice of the local consultant Diabetes team.
6.7	Other endocrine drugs	Quinagolide tablets 50 micrograms, 75 micrograms (Starter Pack)
13.2	Emollient and barrier preparations	Epaderm Ointment
11.8	Miscellaneous ophthalmic preparations	Optrex Optimist Eye Spray (for people with neurological conditions unable to use eye drops or ointments)

SCHEDULE 2

Reg. 1(b)

PHARMACEUTICAL BENEFITS TO BE SUBSTITUTED IN THE SCHEDULE TO
THE 2004 REGULATIONS

Column 1: British National Formulary (BNF) Section	Column 2: Heading	Column 3: Current Pharmaceutical Benefit	Column 4: New Pharmaceutical Benefit
4.1.1	Hypnotics	Melatonin oral solution 10mg/5ml, Melatonin modified release tablets 2 mg: to be prescribed or initiated only by CAMHS consultants and for under 18s only	Melatonin oral solution 10mg/5ml or Melatonin modified release tablets 2mg; each to be prescribed or initiated only by CAMHS consultants or Consultant Paediatricians and for under 18s only.
7.2	Treatment of vaginal and vulval conditions	Estradiol_Vag Ring 2mg	Estradiol 7.5mg/24 hours, vaginal delivery system

EXPLANATORY NOTE

(This note is not part of the Regulations)

These Regulations add drugs to the list of drugs that may be prescribed as pharmaceutical benefit and amend the permissible prescribing of two drugs already on that list

These Regulations come into force on the 14th April, 2021.